$437.44
-3.54-0.80%
At close: -
$437.44
0.000.00%
After Hours: Apr 25, 4:00 PM EDT
Comments
Loading...
IDEXX Laboratories Analyst Ratings and Price Targets | NASDAQ:IDXX | Benzinga
IDEXX Laboratories Inc has a consensus price target of $534.09 based on the ratings of 11 analysts. The high is $650 issued by Goldman Sachs on January 17, 2024. The low is $420 issued by Stifel on April 14, 2025. The 3 most-recent analyst ratings were released by Stifel, Piper Sandler, and Barclays on April 14, 2025, February 10, 2025, and February 4, 2025, respectively. With an average price target of $483.33 between Stifel, Piper Sandler, and Barclays, there's an implied 10.49% upside for IDEXX Laboratories Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Piper Sandler
Barclays
B of A Securities
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for IDEXX Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/14/2025 | Buy Now | -3.99% | Stifel | Jonathan Block71% | $450 → $420 | Maintains | Hold | Get Alert |
| 02/10/2025 | Buy Now | 16.59% | Piper Sandler | David Westenberg59% | $435 → $510 | Maintains | Neutral | Get Alert |
| 02/04/2025 | Buy Now | 18.87% | Barclays | Balaji Prasad53% | $481 → $520 | Maintains | Overweight | Get Alert |
| 02/04/2025 | Buy Now | 22.3% | B of A Securities | Michael Ryskin46% | $475 → $535 | Maintains | Neutral | Get Alert |
| 01/29/2025 | Buy Now | 25.73% | Morgan Stanley | Erin Wright76% | $559 → $550 | Maintains | Overweight | Get Alert |
| 12/02/2024 | Buy Now | 14.3% | Leerink Partners | Daniel Clark32% | → $500 | Initiates | → Outperform | Get Alert |
| 11/04/2024 | Buy Now | -0.56% | Piper Sandler | David Westenberg59% | $520 → $435 | Reiterates | Neutral → Neutral | Get Alert |
| 11/04/2024 | Buy Now | 9.96% | Barclays | Balaji Prasad53% | $570 → $481 | Maintains | Overweight | Get Alert |
| 10/11/2024 | Buy Now | 31.45% | JP Morgan | Chris Schott59% | $630 → $575 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | 14.3% | Stifel | Jonathan Block71% | $510 → $500 | Maintains | Hold | Get Alert |
| 08/14/2024 | Buy Now | 18.87% | Piper Sandler | David Westenberg59% | $600 → $520 | Maintains | Neutral | Get Alert |
| 07/25/2024 | Buy Now | 32.59% | BTIG | Mark Massaro72% | → $580 | Initiates | → Buy | Get Alert |
| 06/24/2024 | Buy Now | 16.59% | Stifel | Jonathan Block71% | $520 → $510 | Maintains | Hold | Get Alert |
| 05/14/2024 | Buy Now | 36.25% | Morgan Stanley | Erin Wright76% | $620 → $596 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 30.3% | Barclays | Balaji Prasad53% | $655 → $570 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 44.02% | JP Morgan | Chris Schott59% | $600 → $630 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 49.73% | Barclays | Balaji Prasad53% | $605 → $655 | Maintains | Overweight | Get Alert |
| 01/30/2024 | Buy Now | 20.02% | Piper Sandler | David Westenberg59% | → $525 | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2024 | Buy Now | 48.59% | Goldman Sachs | Nathan Rich43% | $500 → $650 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | 20.02% | Piper Sandler | David Westenberg59% | $520 → $525 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 14.3% | Goldman Sachs | Nathan Rich43% | $578 → $500 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | 25.73% | JP Morgan | Chris Schott59% | $600 → $550 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 35.33% | Barclays | Balaji Prasad53% | $590 → $592 | Maintains | Overweight | Get Alert |
| 10/30/2023 | Buy Now | 5.16% | Stifel | Jonathan Block71% | $500 → $460 | Maintains | Hold | Get Alert |
| 09/15/2023 | Buy Now | 14.3% | Stifel | Jonathan Block71% | $525 → $500 | Maintains | Hold | Get Alert |
| 08/03/2023 | Buy Now | 37.16% | Morgan Stanley | Erin Wright76% | $590 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 37.16% | JP Morgan | Chris Schott59% | $550 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 37.16% | Atlantic Equities | Steve Chesney56% | → $600 | Downgrade | Overweight → Neutral | Get Alert |
| 06/07/2023 | Buy Now | 37.16% | Atlantic Equities | Steve Chesney56% | → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2023 | Buy Now | 37.16% | Atlantic Equities | Steve Chesney56% | → $600 | Reiterates | → Overweight | Get Alert |
| 03/23/2023 | Buy Now | 34.88% | Morgan Stanley | Erin Wright76% | $543 → $590 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | 34.88% | Barclays | Balaji Prasad53% | $582 → $590 | Maintains | Overweight | Get Alert |
| 02/07/2023 | Buy Now | 25.73% | JP Morgan | Chris Schott59% | $525 → $550 | Maintains | Overweight | Get Alert |
| 02/07/2023 | Buy Now | 37.16% | Atlantic Equities | Steve Chesney56% | $470 → $600 | Maintains | Overweight | Get Alert |
| 01/25/2023 | Buy Now | 21.16% | Goldman Sachs | Nathan Rich43% | $465 → $530 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 24.13% | Morgan Stanley | Erin Wright76% | $573 → $543 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 7.44% | Atlantic Equities | Steve Chesney56% | $490 → $470 | Maintains | Overweight | Get Alert |
| 10/17/2022 | Buy Now | 2.87% | JP Morgan | Chris Schott59% | $525 → $450 | Maintains | Overweight | Get Alert |
| 08/05/2022 | Buy Now | 33.05% | Barclays | Balaji Prasad53% | $700 → $582 | Maintains | Overweight | Get Alert |
| 08/04/2022 | Buy Now | 30.99% | Morgan Stanley | Erin Wright76% | $603 → $573 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 12.02% | Atlantic Equities | Steve Chesney56% | $500 → $490 | Maintains | Overweight | Get Alert |
| 07/26/2022 | Buy Now | -3.99% | Piper Sandler | David Westenberg59% | $440 → $420 | Maintains | Overweight | Get Alert |
| 07/25/2022 | Buy Now | -5.13% | Stifel | Jonathan Block71% | $500 → $415 | Downgrade | Buy → Hold | Get Alert |
| 07/21/2022 | Buy Now | -0.56% | Goldman Sachs | Nathan Rice58% | $530 → $435 | Upgrade | Neutral → Buy | Get Alert |
| 07/12/2022 | Buy Now | 0.59% | Piper Sandler | David Westenberg59% | → $440 | Initiates | → Overweight | Get Alert |
| 06/24/2022 | Buy Now | 14.3% | Stifel | Jonathan Block71% | $575 → $500 | Maintains | Buy | Get Alert |
| 05/19/2022 | Buy Now | 21.16% | Goldman Sachs | Nathan Rice58% | $615 → $530 | Maintains | Neutral | Get Alert |
| 05/05/2022 | Buy Now | 37.85% | Morgan Stanley | Erin Wright76% | $732 → $603 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 7.44% | B of A Securities | Michael Ryskin46% | $550 → $470 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for IDEXX Laboratories (IDXX) stock?
The latest price target for IDEXX Laboratories (NASDAQ:IDXX) was reported by Stifel on April 14, 2025. The analyst firm set a price target for $420.00 expecting IDXX to fall to within 12 months (a possible -3.99% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
The latest analyst rating for IDEXX Laboratories (NASDAQ:IDXX) was provided by Stifel, and IDEXX Laboratories maintained their hold rating.
When was the last upgrade for IDEXX Laboratories (IDXX)?
The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.
When was the last downgrade for IDEXX Laboratories (IDXX)?
The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on April 14, 2025 so you should expect the next rating to be made available sometime around April 14, 2026.
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $450.00 to $420.00. The current price IDEXX Laboratories (IDXX) is trading at is $437.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
